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of this disparity, we aimed to re-examine the clinical usefulness of
HA products, from the perspective of their relative efﬁcacy when
compared against Corticosteroid (CS) injections, a widely used
intervention which clinicians have considerable familiarity with and
are widely recommended in consensus statements. Additionally,
we sought to determine how their relative efﬁcacy performs over
time, as prior trials suggest that they have different response
trajectories.
Methods: We searched Medline, EMBASE, CINAHL, BIOSIS and
Cochrane database from inception to February 2009 for human
randomized clinical trials comparing HA with CS for knee OA. We
also hand searched review articles, manuscripts and supplements
from medical journals and contacted authors for unpublished data.
Two reviewers (RRB, NSN) independently performed data extrac-
tion and scored each trial using the Jadad scale. We computed
relative effect sizes for pain change from baseline to weeks (wk)
2, 4, 8, 12 and 26 for each study using Hedges’ g statistic.
Effect sizes were pooled using a random effects model. Sensi-
tivity analyses were performed among trial subsets that reported
intent-to-treat (ITT) analysis, blinding methodology and those that
compared Hyalgan® with Depo-Medrol®.
Results: The 7 eligible trials included 606 participants with an age
range of 49 to 72 years. They included HA (n = 312; 101 men, 211
women) and CS (n = 294; 99 men, 195 women). Jadad quality
scores ranged from 2 to 4 and were published between 1987
and 2004. The relative effect size favored CS at wk 2 -0.39 (95%
conﬁdence interval -0.65, -0.12) and suggested equal efﬁcacy at
wk 4 (-0.01; -0.23, 0.21). At wk 8 (0.22; -0.05, 0.49), wk 12 (0.35;
0.03, 0.66) and wk 26 (0.39; 0.18, 0.59) it favored HA.
The results were consistent when we conﬁned the pooled analysis
to the 5 trials that reported ITT (Table 1). The relative effect size
favored CS at wk 2 (-0.39; -0.65, -0.12) and suggested equal
efﬁcacy at wk 4 (-0.004; -0.30, 0.30). At wk 8 (0.22; -0.05, 0.49),
wk 12 (0.27; -0.16, 0.69) and wk 26 (0.38; 0.15, 0.60) it favored
HA. Results were consistent when we conﬁned the pooled analysis
to the 4 trials that reported blinding methodology. It favored CS
at wk 2 (-0.36; -0.82, 0.10) and suggested equal efﬁcacy at wk 4
(-0.11; -0.42, 0.21) and wk 8 (0.08; -0.27, 0.43). At wk 12 (0.27;
-0.16, 0.70) and wk 26 (0.37; 0.16, 0.59) it favored HA. When
we conﬁned the pooled analysis to the 4 trials that compared
Hyalgan® with Depo-Medrol®, it favored CS at wk 2 (-0.43; -0.79,
-0.08) and suggested equal efﬁcacy at wk 4 (0.01; -0.43, 0.45). At
wk 8 (0.21; -0.18, 0.60) it favored HA.
Table 1. Pooled relative effect sizes (95% CI)
Primary Analysis ITT Analysis Blinding
7 trials 5 trials 4 trials
Wk 2 -0.39 (-0.65, -0.12) -0.39 (-0.65, -0.12) -0.36 (-0.82, 0.10)
Wk 4 -0.01 (-0.23, 0.21) -0.004 (-0.30, 0.30) -0.11 (-0.42, 0.21)
Wk 8 0.22 (-0.05, 0.49) 0.22 (-0.05, 0.49) 0.08 (-0.27, 0.43)
Wk 12 0.35 (0.03, 0.66) 0.27 (-0.16, 0.69) 0.27 (-0.16, 0.70)
Wk 26 0.39 (0.18, 0.59) 0.38 (0.15, 0.60) 0.37 (0.16, 0.59)
Figure 1. Graph showing relative effect size at each time point (95% CI).
Conclusions: This meta-analysis shows a pattern of relative efﬁ-
cacy that varies over time. In the short term (up to 4 weeks), CS
appears to be more effective for pain. By wk 4 the two approaches
have equal efﬁcacy, but by wk 8 and beyond HA products have
greater relative effects (Fig 1). The possible limitations of our anal-
ysis would be the inﬂuence of methodological issues among the
individual trials and the use of different formulations and doses
of CS. We addressed these issues by performing several sensi-
tivity analyses using these variables. Awareness of this pattern
of response will be useful to the clinician when formulating a
therapeutic plan for patients with knee OA.
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Purpose: To compare the efﬁcacy and safety of ultrasound-guided
local injections of hyaluronic acid (HA) (Suplasyn® 500-1000
kDa) and betamethasone in the management of patients with
osteoarthritis of the thumb.
Methods: Patients of both sexes, aged > 40 years, diagnosed
with osteoarthritis of the thumb (Kellgren-Lawrence grade II and III)
according to the ACR criteria were included in the study. Patients
were randomized (1:1) to ultrasound-guided local treatment with
HA or betamethasone. A total of three local injections of active
medication were scheduled at 7-day intervals. Paracetamol, 2
g/day, was allowed as rescue medication. Assessments performed
at baseline and at 7, 14, 30, 90 and 180 days included pain
evaluation with a 100-mm visual analogue scale (VAS), Dreiser’s
functional index (score 0-30), and global evaluation of efﬁcacy
by the investigator and the patient. The Student’s t test or the
Mann-Whitney U test for continuous variables and the chi-square
test for categorical variables were used.
Results: In both study groups (40 patients in each group), VAS
scores at the follow-up assessments showed a signiﬁcant de-
crease as compared with baseline, but differences between the
groups of HA and betamethasone were not statistically signiﬁ-
cant. In both groups, maximal pain relief occurred at 30 days.
Scores of the Dreiser’s functional index decreased signiﬁcantly in
both groups as compared with baseline, but at 90 days in which
maximal improvement was also seen, HA-treated patients scored
5.50 and betamethasone-treated patients scored 10.0 (P = 0.04).
A trend towards a greater clinical improvement in the HA group
compared with the betamethasone group was also recorded at
90 days in the patients’ assessment of efﬁcacy (P = 0.08). Local
adverse events did not occur.
Conclusions: Ultrasound-guided local injections of HA and be-
tamethasone were both effective and well tolerated for the man-
agement of patients with osteoarthritis of the thumb, although HA
seemed to provide better functional beneﬁts than betamethasone.
